Platinum-sensitive relapsed epithelial ovarian cancer: Not all the patients benefit from reinduction with carboplatin and paclitaxel

Medical Science Monitor

Volumn 16, Issue 11, 2010, Pages 549-554

  Milović Kovačević, Marijana ^a   Stamatovic, Ljiljana ^a   Popov, Ivan ^a   Radošević Jelić, Ljiljana ^a   Kezic, Iva ^a  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

Author keywords

Metastatic disease; Platinum based chemotherapy; Platinum sensitive ovarian cancer; Re treatment

Indexed keywords

CARBOPLATIN; PACLITAXEL; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MEGESTROL ACETATE; PLATINUM DERIVATIVE; TAMOXIFEN; ANTINEOPLASTIC AGENT;

ADULT; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; ASCITES; CANCER CENTER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RELAPSE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; EPITHELIAL OVARIAN CANCER; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LIVER METASTASIS; LYMPH NODE METASTASIS; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUTROPENIA; OVARY CANCER; PERITONEUM METASTASIS; RETREATMENT; RETROSPECTIVE STUDY; SENSORY NEUROPATHY; SERBIA; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG FATALITY; DRUG SENSITIVITY; DRUG TOLERABILITY; EPITHELIUM TUMOR; METASTASIS; PERIPHERAL NEUROPATHY; TREATMENT RESPONSE; OVARY TUMOR; PATHOLOGY; RECURRENT DISEASE; REMISSION; SURVIVAL RATE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARBOPLATIN; FEMALE; HUMANS; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; PACLITAXEL; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 78249288754     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Pfisterer J, Ledermann JA: Management of platinum-sensitive recurrent ovarian cancer. Semin Oncol, 2006; 33(6): 12-6.
2. Heintz AP, Odicino F, Maisonneuve P et al: Carcinoma of the ovary. Int J Gynaecol Obstet, 2003; 83(1): 135-66.
3. Stewart DJ: Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol, 2007; 63: 12-31.
4. Hilpert F, Krause G, Venholff L et al: Epithelial ovarian cancer. Ther Umsch, 2007; 64(7): 375-30.
5. Colombo N, Van Gorp T, Parma G et al: Ovarian cancer. Crit Rev Oncol Hematol, 2006; 60(2): 159-79.
6. ESMO Guidelines Task Force: minimum clinical recommendations for diagnosis, treatment and follow-up of ovarian cancer. Switzerland: ESMO;2002. Available at:http://www.esmo.org/reference/referenceGuidelines/html/ MCR6.htm [accessed November 28, 2005].
7. Kosmas C, Tsavaris N: A simplified premedication protocol for onehour paclitaxel infusion in various combinations. Med Sci Monit, 2006; 12(11): CR462-66.
8. Morgan RJ Jr, Alvarez RD, Armstrong DK et al: Ovarian cancer.Clinical practice guidelines in oncology.National Comprehensive Cancer Network. J Natl Compr Canc Netw, 2008; 6(8): 766-94.
9. Tanguay JS, Ansari J, Buckley L, Fernando I: Epithelial ovarian cancer: role of pegylated liposomal Doxorubicin in prolonging the platinum- free interval and cancer antigen 125 trends during treatment. Int J Gynecol Cancer, 2009; 19(3): 361-66.
10. Markman M, Markman J, Webster K et al: Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol, 2004; 22(15): 3120-25.
11. Colombo N, Gore M: Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapy. Crit Rev OncolHematol, 2007; 64(2): 129-38.
12. Bookman MA, Brady MF, McGuire WP et al: Evaluation of new platinumbased treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol, 2009; 27(9): 1419-25.
13. Eisenhauer EA,Vermorken JB, Van Glabbeke M: Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol, 1997; 8: 963-68.
14. Eichbaum MH, Weiss LM, Bruckner T et al: Prognostic impact of emoglobin levels before and during carboplatin/taxane-based chemotherapy in patients with primary invasive epithelial ovarian cancer. Med Sci Monit, 2009; 15(4): CR156-63.
15. Eisenhauer EA, Therasse P, Bogaerts J et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 2009; 45(2): 228-47.
16. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events v3.0 (CTCAE), National Cancer Institute, August 9, 2006.
17. Rao GG, Miller DS: Hormonal therapy in epithelial ovarian cancer. Expert Rev Anticancer Ther, 2006; 6(1): 43-47.
18. Markman M, Rothman R, Hakes T et al: Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol, 1991; 9: 389-93.
19. Canistra SA: Is there a "best"choice of second-line agent in treatment of recurrent, potentially platinum-sensitive ovarian cancer? J Clin Oncol, 2002; 20(5): 1158-60.
20. Parmar MK, Ledermann JA, Colombo N et al: Paclitaxel plus platinumbased chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet, 2003; 361: 2099-106.
21. Rustin GJ, Nelstrop AE, McClean P et al: Defining response of ovarian carcinoma to initial chemotherapy according to serum Ca125. J Clin Oncol, 1996; 14(5): 1545-51.
22. Kumar P, Rehani MM, Kumar L et al: Tumor marker CA-125 as an evaluator and response indicator in ovarian cancer: its quantitative correlation with tumor volume. Med Sci Monit, 2005; 11(2): CR84-89.
23. Bookman MA: Trials with impact on clinical management: first line. Int J Gynecol Cancer, 2009;19(2): 55-62.
24. Zhao XD, Wei FH, Zhang Y et al: Treatment of platinum-resistant recurrent ovarian cancer using a "predictive molecule targeted routine chemotherapy" system. Chin Med J (Engl), 20095; 122(23): 2856-60.
25. Bookman MA: Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy. Oncologist, 1999; 4(2): 87-94.